5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice

Salvage chemotherapy for patients with unresectable pancreatic cancer (UR-PC) who have been treated with gemcitabine and nab-paclitaxel (GnP), and 5-fluorouracil (5-FU)/l-leucovorin (LV) plus nanoliposomal irinotecan (nal-IRI), has not been fully established. We retrospectively reviewed data from 17...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Takuo Yamai, Kenji Ikezawa, Yasuharu Kawamoto, Takeru Hirao, Sena Higashi, Kazuma Daiku, Shingo Maeda, Yutaro Abe, Makiko Urabe, Yugo Kai, Ryoji Takada, Tasuku Nakabori, Hiroyuki Uehara, Kazuyoshi Ohkawa
Formatua: Artikulua
Hizkuntza:English
Argitaratua: MDPI AG 2022-04-01
Saila:Current Oncology
Gaiak:
pancreatic cancer
FOLFOX
chemotherapy
Sarrera elektronikoa:https://www.mdpi.com/1718-7729/29/4/216

Internet

https://www.mdpi.com/1718-7729/29/4/216

Antzeko izenburuak